ArticleAging2023

PTPRD mutation is a prognostic biomarker for sensitivity to ICIs treatment in advanced non-small cell lung cancer.

Zhixuan Ren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.